Twin Focus Capital Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-11,323
Closed -$415K 211
2023
Q2
$415K Buy
11,323
+87
+0.8% +$3.39K 0.08% 127
2023
Q1
$458K Buy
11,236
+30
+0.3% +$1.3K 0.09% 112
2022
Q4
$574K Buy
11,206
+11
+0.1% +$527 0.12% 93
2022
Q3
$490K Buy
11,195
+478
+4% +$23.2K 0.12% 96
2022
Q2
$562K Buy
10,717
+102
+1% +$5.2K 0.13% 94
2022
Q1
$550K Buy
10,615
+55
+0.5% +$2.85K 0.11% 99
2021
Q4
$624K Buy
10,560
+1,328
+14% +$65.8K 0.12% 90
2021
Q3
$397K Buy
9,232
+135
+1% +$5.98K 0.09% 113
2021
Q2
$356K Buy
9,097
+1,335
+17% +$51.9K 0.08% 123
2021
Q1
$281K Sell
7,762
-1,321
-15% -$46.9K 0.08% 118
2020
Q4
$334K Buy
9,083
+1,983
+28% +$72.7K 0.1% 113
2020
Q3
$247K Sell
7,100
-2,560
-27% -$89.8K 0.09% 115
2020
Q2
$300K Buy
9,660
+1,593
+20% +$54.1K 0.12% 101
2020
Q1
$250K Buy
+8,067
New +$275K 0.12% 114
2015
Q2
Sell
-6,746
Closed -$223K 102
2015
Q1
$223K Sell
6,746
-3,461
-34% -$110K 0.18% 72
2014
Q4
$302K Buy
10,207
+603
+6% +$17.3K 0.35% 62
2014
Q3
$269K Buy
9,604
+2,168
+29% +$60.8K 0.26% 71
2014
Q2
$209K Buy
+7,436
New +$212K 0.23% 80

Other funds holding PFE

Twin Focus Capital Partners's PFE Position: Q3 2023 in Review

Twin Focus Capital Partners sold out of Pfizer (PFE) in Q3 2023, closing a stake of 11,323 shares — an estimated $415K sold.

Twin Focus Capital Partners first reported a position in PFE in Q2 2014 and held it in 18 quarters. The position peaked at $624K in Q4 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Twin Focus Capital Partners reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Twin Focus Capital Partners sold 11,323 Pfizer shares in Q3 2023, an estimated $415K.
  • Twin Focus Capital Partners first reported a position in Pfizer in Q2 2014 and held it in 18 quarters.
  • Twin Focus Capital Partners's Pfizer position peaked at $624K in Q4 2021.
  • 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Twin Focus Capital Partners's 13F filing for Q3 2023, filed 13 Nov 2023.